The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 348:2455-2456 June 12, 2003 Number 24
NextNext

Clinical Trials and Rare Diseases
Stephen W. Lagakos, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Gallin, J. I.
-PubMed Citation
In this issue of the Journal, Gallin and colleagues1 report the results of a clinical trial of itraconazole for the prevention of severe fungal infection in children and adults with chronic granulomatous disease. This trial required 10 years to enroll just 39 patients. The study illustrates some of the problems and options that arise in the design of clinical trials of new therapies for rare diseases.

When patients are scarce, one option is to design the study so that patients serve as their own controls. For example, in a two-group crossover study,2 each patient receives the two study treatments sequentially . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.